Table 3 Pattern of antidiabetic drug treatment in 2006 and 2012
2006 | 2012 | P* | |
|---|---|---|---|
Lifestyle intervention only | 38 (4.1) | 11 (1.1) | 0.001 |
OAD only | 597 (63.6) | 573 (56.5) | 0.7 |
OAD Monotherapy** | 165 (27.6) | 182 (31.8) | 0.4 |
Combination (2 drugs)** | 307 (51.5) | 245 (42.7) | |
Combination (3 drugs)** | 125 (20.9) | 146 (25.5) | |
Metformin | 627 (66.8) | 816 (80.4) | < 0.001 |
Sulphonylurea | 416 (44.3) | 270 (26.6) | < 0.001 |
TZD | 159 (17.0) | 50 (4.9) | < 0.001 |
Glinide | 118 (12.5) | 27 (2.7) | < 0.001 |
Acarbose | 73 (7.8) | 22 (2.2) | < 0.001 |
DPP-IV inhibitor | 0 | 350 (34.5) | |
GLP-1 agonist | 0 | 39 (3.8) | |
Insulin | 303 (32.3) | 432 (42.6) | 0.09 |
1 injection# | 91 (30.0) | 126 (29.2) | 0.001 |
2 injections# | 118 (38.9) | 83 (19.3) | |
≥ 3 Injections# | 94 (31.1) | 222 (51.5) | |
Insulin analog# | 151 (49.8) | 315 (72.9) | <0.001 |
Units per Kg of body weight | 0.5 (0.3) | 0.5 (0.3) | 0.87 |